Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials

Hormonal therapies for receptor positive-breast and prostate cancer patients have shown clinical efficacy but also several side effects including osteoporosis, loss of bone mass and increased fracture risk. Denosumab represents an anti RANKL (receptor activator of nuclear factor-kB ligand) monoclona...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Bone Oncol
Main Authors: Galvano, Antonio, Scaturro, Dalila, Badalamenti, Giuseppe, Incorvaia, Lorena, Rizzo, Sergio, Castellana, Luisa, Cusenza, Stefania, Cutaia, Sofia, Santini, Daniele, Guadagni, Fiorella, Roselli, Mario, Gori, Stefania, Latteri, Mario Adelfio, Bazan, Viviana, Giulia, Letizia Mauro, Russo, Antonio
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700425/
https://ncbi.nlm.nih.gov/pubmed/31440444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2019.100252
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados